Medical Oncologist
Dr Georgios Evangelou
MD, MSc, PhD · Medical Oncologist
Dr Georgios Evangelou is a Medical Oncologist with a clinical and academic focus on lung cancer, neuroendocrine neoplasms and gastrointestinal malignancies. He works at the Third Department of Medicine, National and Kapodistrian University of Athens, at Sotiria General Hospital for Chest Diseases.
Clinical Career & Scientific Work
Clinical Work & Positions of Responsibility
He works in the Oncology Unit of the Third Department of Medicine, National and Kapodistrian University of Athens, at Sotiria General Hospital for Chest Diseases, with clinical activity in lung cancer, neuroendocrine neoplasms and gastrointestinal malignancies.
He is the Coordinator and Scientific Lead of the Neuroendocrine Neoplasms Clinic of the Third Department of Medicine, National and Kapodistrian University of Athens, at Sotiria General Hospital for Chest Diseases.
He also works as an external consultant Medical Oncologist at Therapis General Hospital. He served as President of the Hellenic Society of Neuroendocrine Tumours from 2021 to 2023.
Education & Academic Training
Medical Degree (MD) — Aristotle University of Thessaloniki
Specialty Training in Medical Oncology — University Hospital of Heraklion
MSc — School of Medicine, National and Kapodistrian University of Athens (NKUA) · Sep 2020
Master’s thesis: “Comparison of the Effectiveness of Oncology Drugs in Clinical Trials with Their Effectiveness in Real-World Data: The Example of Non-Small Cell Lung Cancer (NSCLC)”
PhD — School of Medicine, National and Kapodistrian University of Athens (NKUA) · Oct 2024
Doctoral dissertation: “Prognostic and Predictive Value of the Immunohistochemical Markers RB1, TP53, Tyrosine Hydroxylase, and microRNAs in Large-Cell Neuroendocrine Carcinoma (LCNEC)”
ESMO Examination — Successfully completed, Copenhagen, 2016
Research & International Activity
His research focuses on pulmonary neuroendocrine neoplasms, thoracic oncology and biomarkers, with emphasis on clinical and translational research. He is the principal investigator of the prospective LANCE study in metastatic LCNEC; its long-term analysis was presented at ESMO Sarcoma and Rare Cancers 2026 and featured in ESMO Breaking Science.